Ketamine

The signature quality of ketamine is unmistakable from the first moments: a progressive, almost mechanical disconnection between mind and body. When insufflated, effects begin within five to ten minutes. A tingling numbness spreads through the face, hands, and feet. The body starts to feel remote — not gone, but observed from a slight remove, as though you have taken one step back from the controls. Sounds develop a hollow, reverberant quality, like hearing the world from inside a cathedral. Movement becomes loose and uncoordinated, and there is often a pleasant sense of physical lightness, as though gravity has been dialed down a few notches.

At low to moderate doses, this is ketamine's "wonky" zone — the state that makes it popular at parties and concerts. There is a floaty, slightly drunken euphoria, enhanced immersion in music, and a disinhibition that feels somewhere between alcohol and a very mild psychedelic. Colors may seem more vivid. Conversations become looser, stranger, more amusing. Some people describe it as making the world feel like a video game — present but slightly unreal. Coordination is impaired enough that walking looks and feels ridiculous, which is part of the charm and part of the danger.

As the dose increases, the experience changes character entirely. The body becomes increasingly abstract — limbs feel like they belong to someone else, or the concept of having limbs at all becomes genuinely confusing. Spatial perception warps dramatically: rooms stretch, ceilings recede, distances become unjudgeable, and the geometry of the environment bends in slow, fluid distortions. Thought patterns fragment from their usual narrative structure. Ideas arrive sideways. Time perception loosens — minutes can feel like hours or collapse into instants.

At higher doses, ketamine produces the k-hole: a state of complete dissociation in which external reality is replaced by an immersive inner landscape. The k-hole is not a hallucination layered on top of reality — it is a wholesale replacement of reality. Users describe traveling through vast geometric spaces, experiencing consciousness as something unanchored from location or identity, encountering entities or scenarios that feel absolutely real in the moment. Time dissolves. Communication with the outside world is impossible. The experience can be transcendent, terrifying, profoundly strange, or all three simultaneously. Many people compare it to a near-death experience, and the comparison is not casual — the phenomenology overlaps significantly with reported NDEs.

The return from deeper ketamine states is gradual and often disorienting. Over thirty to sixty minutes, embodiment reassembles itself piece by piece. There is typically grogginess, physical uncoordination, and sometimes nausea — particularly if you try to move too quickly. Visual distortions fade slowly. Higher doses frequently produce anterograde amnesia, leaving patchy or missing memories of the peak experience itself.

The afterglow is distinctive: a period of quiet, slightly detached calm. The emotional volume of the world has been turned down. Worries feel temporarily distant. Many users — and a growing body of clinical research — note that this afterglow can extend into genuine mood improvement lasting days or even weeks, particularly in people with depression. It is this afterglow, not the k-hole itself, that drives much of ketamine's therapeutic interest.

NMDA Receptor Antagonism

Ketamine's defining mechanism is non-competitive, use-dependent blockade of the NMDA (N-methyl-D-aspartate) receptor, a ligand-gated ion channel central to excitatory neurotransmission and synaptic plasticity. "Use-dependent" means ketamine can only enter and block the channel when it is already open — it waits for the receptor to fire, then plugs the hole. This silences glutamatergic signaling across the cortex, hippocampus, and thalamus, disrupting thalamocortical gating — the process by which the thalamus filters sensory information before relaying it to the cortex. When that filter breaks down, sensory inputs decouple from the unified sense of self. At moderate doses, you feel detached from your body. At high doses, the concept of having a body stops making sense entirely.

The Glutamate Surge and Antidepressant Mechanism

Blocking NMDA receptors on GABAergic interneurons paradoxically increases glutamate release in the prefrontal cortex through disinhibition. This surge activates AMPA receptors, triggering BDNF release, mTOR pathway activation, and rapid synaptogenesis — new dendritic spines and synaptic connections that reverse the synaptic atrophy characterizing depression. A 2026 PET imaging study directly observed AMPA receptor changes in mood-related brain regions after ketamine, with receptor reorganization correlating directly with symptom improvement. A 2025 Science study showed enhanced ERK activity extends ketamine's antidepressant window by augmenting this synaptic plasticity.

Additional Receptor Targets

Ketamine is not a one-target drug. It also binds mu, kappa, and delta opioid receptors (contributing to analgesia and potentially to its dependence liability), sigma-1 receptors (implicated in hallucinogenic and neuroprotective effects), D2 dopamine receptors (contributing to stimulant-like and reinforcing properties), HCN channels (relevant to analgesic mechanisms), and nicotinic acetylcholine receptors (nAChR antagonism). This polypharmacology helps explain why ketamine's subjective effects are so distinct from "cleaner" NMDA antagonists.

Stereochemistry

Racemic ketamine is a 50/50 mix of S-ketamine (esketamine) and R-ketamine (arketamine). Esketamine has roughly twice the anesthetic potency and is the dominant NMDA antagonist — it is the basis for Spravato (FDA-approved for treatment-resistant depression). Arketamine, the less-studied enantiomer, is generating significant research interest: preliminary clinical data suggest it may produce longer-lasting antidepressant effects with fewer dissociative side effects and lower abuse potential, though results from human trials remain mixed and larger studies are needed.

Pharmacokinetics

Peak plasma concentrations arrive within 1 minute (IV), 5-15 minutes (IM), 15-30 minutes (insufflation), and 30-45 minutes (oral). Oral bioavailability is notably low at roughly 17-20% due to extensive first-pass hepatic metabolism. The elimination half-life is approximately 2-3 hours. Ketamine is metabolized primarily to norketamine (an active metabolite with about one-third the potency and a longer half-life), then further to dehydronorketamine and hydroxynorketamine metabolites — the latter of which may contribute independently to antidepressant effects.

Synthesis and Early Development

Ketamine was synthesized in 1962 by Calvin Lee Stevens at Parke-Davis laboratories in Detroit, Michigan. The goal: find a safer alternative to phencyclidine (PCP), which worked as an anesthetic but left patients severely delirious with garbled speech and prolonged hallucinations. Stevens modified PCP's structure, producing a series of arylcyclohexylamine derivatives. Ketamine (CI-581) emerged as the most promising — shorter-acting, with far milder emergence reactions. Edward Domino and Guenter Corssen conducted first human trials in 1964, coining the term "dissociative anesthesia." It was patented in 1966 and received FDA approval in 1970 as Ketalar.

The Battlefield and the Operating Room

Ketamine's first large-scale deployment was during the Vietnam War, where it earned the nickname "the buddy drug" — soldiers carried it to inject wounded comrades, providing immediate pain relief without morphine's respiratory depression risk. It became the world's most widely used anesthetic, particularly valuable in low-resource settings because it maintains airway reflexes and cardiovascular stability. The WHO placed it on its List of Essential Medicines, where it remains today.

Recreational Discovery and Cultural Spread

Ketamine's psychoactive properties were explored by psychedelic researchers in the 1970s, notably documented in Marcia Moore and Howard Altounian's Journeys into the Bright World (1978) and John Lilly's The Scientist (1978). It entered UK rave and club culture in the late 1980s-1990s alongside MDMA, and by the 2000s had achieved widespread global recreational use. The US placed it in Schedule III in 1999.

The Antidepressant Revolution

The discovery that ketamine could rapidly lift treatment-resistant depression — emerging from clinical trials at Yale in the early 2000s — represented a paradigm shift in psychiatry. For the first time, a drug produced meaningful antidepressant effects within hours rather than weeks, via a completely novel mechanism (glutamate/AMPA rather than serotonin/norepinephrine). Esketamine (Spravato) received FDA approval in 2019 for treatment-resistant depression. As of 2026, arketamine is in clinical trials as a next-generation antidepressant, and oral ketamine formulations are showing promise in expanding access beyond infusion clinics.